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Hemodynamic profiles in treatment-naive arterial
hypertension and their clinical implication for
treatment choice: an exploratory post hoc analysis
Delphine Glinza, Claudia Bläsia, Andrea Villigerb, Andrea Meienberga, Thenral Socratesa,
Otmar Pfisterd, Michael Mayra, Manuel Haschkec, Annina Salome Vischera,, and Thilo Burkarda,d,
Objective: Noninvasive thoracic bioimpedance by the
HOTMAN System estimates hemodynamic modulators and
expresses them as hemodynamic profiles. Aims of this
analysis were to describe hemodynamic profiles among
treatment-naive hypertensive patients compared with
normotensive controls and to investigate whether a
hemodynamic-guided choice of therapy improves blood
pressure (BP) control within 4 weeks.
Method: This exploratory post hoc analysis used data of a
randomized parallel-group trial including 80 outpatients
with newly diagnosed arterial hypertension (AHT),
randomized to four antihypertensive first-line
monotherapies, and 20 age-matched and sex-matched
normotensive controls. Hemodynamic profiles were
measured at baseline and after four weeks of treatment. On
the basis of the hemodynamic profiles, the most appropriate
pharmacological treatment was determined retrospectively
and patients were categorised to have received concordant
(ConTG) or discordant treatment (DisTG).
Results: In the hypertensive group, hypervolemia with
vasoconstriction was the predominant hemodynamic
profile in 48% of patients and hypervolemia without
vasoconstriction in 45%, compared with 15 and 50%,
respectively, in the control group. After 4 weeks of
treatment, the mean (SD) 24-h BP was 129.9 (11.0)/
81.5 (8.0) mmHg in the DisTG vs. 133.9 (12.3)/84.0
(9.1) mmHg in the ConTG (P¼0.158/0.222). The mean
24-h BP reductions were 9.7 (10.1)/5.0 (6.2) mmHg
in the DisTG and 12.4 (14.8)/6.9(6.9) mmHg in the
ConTG (P¼0.353/0.223). After 4 weeks of treatment, the
BP control rate was 53.7% (43/80) among all, 55.7% (29/
52) in the DisTG and 48% (12/25) in the ConTG
(P¼0.628).
Conclusion: Our findings do not support the hypothesis
that personalized treatment initiation based on
hemodynamic profiles improves BP control in newly
diagnosed hypertensive outpatients.
Keywords: antihypertensive therapy, hemodynamic
profiles, HOTMAN system, hypertension
Abbreviations: ABPM, 24-h ambulatory blood pressure
monitoring; ACEi, angiotensin-converting enzyme inhibitor;
ARB, angiotensin-receptor blocker; BP, blood pressure;
CCB, calcium-channel blocker; CI, cardiac index; ConTG,
concordant treatment group; DisTG, discordant treatment
group; EPCI, ejection phase contractility index; ESH,
European Society of Hypertension; HCT,
hydrochlorothiazide; HOTMAN, Hemodynamic and Oxygen
Transport Monitoring & Management Systems; HR, heart
rate; ICG, impedance cardiography; IQR, interquartile
range; ISI, inotropic state index; LSWI, left stroke work
index; MAP, mean arterial pressure; OBP, office blood
pressure; PWA, pulse wave analysis; RAAS, renin—
angiotensin–aldosterone system; RCT, randomized
controlled trial; SD, standard deviation; SI, stroke index;
SSVRI, stroke systemic vascular resistance index; TEB,
thoracic electrical bioimpedance; TFC, thoracic fluid
conductivity
INTRODUCTION
A
rterial hypertension is a worldwide highly prevalent
chronic disease [1]. Achieving blood pressure (BP)
control is a challenge in everyday clinical practice,
which is tackled by various strategies including different
combinations of drugs [2]. Despite this, BP control rates
have remained poor worldwide. As shown in previous
studies, only 40% of patients with hypertension world-
wide are treated and only 35% of these patients have a
controlled BP of less than 140/90 mmHg [3]. This failure to
achieve BP control in most hypertensive patients shows that
we need new approaches to improve treatment especially
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considering the increasingly tighter BP goals [4]. One
approach, favored in recent guidelines, is to start empiric
combination drug therapy to achieve rapid BP control,
which is reasonable on a population level but may disre-
gard the complex pathophysiology of hypertension in the
individual patient [4,5]. An alternative approach might be to
individually tailor therapy based on hemodynamic param-
eters.
Physiologically, BP is determined by intravascular vol-
ume, cardiac output, and peripheral vascular resistance
[6,7]. Alterations of these hemodynamic modulators or a
disbalance thereof lead to elevated blood pressure [8].
These hemodynamic modulators can be measured nonin-
vasively by thoracic electrical bioimpedance (TEB). TEB
was first used in the 1960s to measure noninvasively cardiac
output in astronauts [9]. In brief, cardiac output is estimated
by changes in thoracic bioimpedance based on the assump-
tion that electric current will mainly travel along large
vessels, that is, the thoracic aorta and the inferior and
superior venae cavae through the thorax. Changes in aortic
diameter during systole and diastole alter these currents,
and therefore, TEB. By the use of mathematical algorithms,
these alterations in TEB can then be used to estimate cardiac
output [10,11]. In addition, various cardiodynamic and
hemodynamic parameters can be derived by entering the
present BP. Noninvasive measurement systems using bio-
impedance have been used in previous studies to deter-
mine/monitor cardiac output [12]. One low-current TEB
device, the HOTMAN System (Hemodynamic and Oxygen
Transport Monitoring & Management Systems, Hemosa-
piens Medical Inc., Sedona, Arizona, USA) may have the
advantage against older devices that it uses a very low
current with digital data signal processing and improved
mathematical algorithms [13]. Additionally, the systems
report not only an estimation of the cardiac output and
other hemodynamic modulators but also generates a hemo-
dynamic profile expressed as hemodynamic map showing
deviations of volemia, inotropy, chronotropy, and vasoac-
tivity from their normal range (Supplementary digital Figure
1, http://links.lww.com/HJH/B545) [10]. The HOTMAN
System has been validated against invasive measurement
(thermodilution method) of the cardiac index (CI) [13] and
has been used in previous studies, for example, to assess
hemodynamic patterns in patients with various forms of
hypertension, in obese patients [14], or to guide treatment
decisions in patients with resistant or uncontrolled hyper-
tension [15–17].
Aim of this study was to describe hemodynamic profiles
among newly diagnosed hypertensive patients compared
with normotensive control patients and to investigate
whether a hemodynamic-guided personalized drug treat-
ment improves BP control within 4 weeks.
METHODS
This is an exploratory post hoc analysis of a randomized,
open-label, parallel-group study in patients with treatment-
naive arterial hypertension. The study was investigating
renin–angiotensin–aldosterone peptide concentrations and
noninvasive hemodynamic measurements at baseline and 4
weeks after initiation of first-line antihypertensive
treatment. The trial was conducted at the Hypertension
Clinic of the Medical Outpatient Department of the Univer-
sity Hospital Basel, Switzerland from April 2015 to
March 2018.
Patient selection
Eighty patients newly diagnosed with primary arterial
hypertension requiring antihypertensive drug treatment
were randomized in a 1 : 1 : 1 : 1 ratio to one out of four
first-line guidelines-recommended treatment groups [18]:
angiotensin-converting enzyme inhibitor (ACEi): peri-
ndopril 5 mg; angiotensin receptor blocker (ARB): olme-
sartan 20 mg; calcium-channel blocker (CCB): amlodipin
5 mg; or hydrochlothiazide (HCT): hydrochlorothiazide
25 mg.
Full inclusion and exclusion criteria can be found in
Supplementary digital Table 1, http://links.lww.com/HJH/
B547. In brief, patients had to be at least 18 years of age and
newly diagnosed with primary grade I or II arterial hyper-
tension, confirmed by 24-h ambulatory blood pressure
monitoring (ABPM) and previously untreated. Diagnostic
work-up to exclude secondary forms of hypertension has
been done according to the 2013 European Society of
Hypertension (ESH) guidelines [18].
Control group
Twenty age-matched and sex-matched healthy and normo-
tensive participants were included as control group with
recruitment in a 4 : 1 fashion. Normotension was confirmed
by ABPM according to the cut-off values of mean 24-h,
awake and asleep BP as defined by the 2013 ESH guidelines
[18].
Trial registration
The trial protocol was approved by local ethics commit-
tee (Ethikkommission Nordwest- und Zentralschweiz
EKNZ 2015-081). The study has been registered in the
US trial registry (clinicaltrials.gov, NCT02449811) and
was performed in accordance with the Declaration of
Helsinki and its amendments, International Conference
on Harmonization, Good Clinical Practice guidelines,
and applicable national laws and regulations. Anony-
mized data supporting the findings of this study are
available from the corresponding author upon reason-
able request.
Study procedure
An overview of the study procedure is shown in Fig. 1.
Patients with primary arterial hypertension confirmed by
ABPM were included into the intervention group.
At baseline, blood tests, office blood pressure (OBP)
measurements, noninvasive hemodynamic measurements
using the thoracic bioimpedance device (HOTMAN System,
Hemo Sapiens Medical Inc., Sedona, Arizona, USA) and
randomization were performed by a study nurse in all
patients. After completion of the measurements, patients
were randomized to one of the four treatment groups,
treating physicians were blinded for the results of the
hemodynamic measurements. After 4 weeks of treatment,
ABPM, OBP, and hemodynamic measurements were
Glinz et al.
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repeated. Hemodynamic measurements were taken in
supine position with two pairs of electrodes positioned
on the upper neck and upper abdomen (giving current) and
two pairs of electrodes at the base of the neck and the
diaphragm level (measurement). After 5min of rest, three
consecutive hemodynamic measurements spaced 2min
apart were recorded together with OBP measurements
performed with a Mobil-O-Graph 24-h PWA (pulse wave
analysis) monitor (IEM) [19].
Hemodynamic data
Of the three hemodynamic measurements, the last one with
the best signal quality (regularity of the pulse curves,
artefact load) was used for analysis. Alterations in the
thoracic impedance were analyzed by the HOTMAN system
providing hemodynamic parameters related to blood flow
[cardiac index (CI)], hemodynamic state [stroke index (SI)],
the heart rate (HR), the afterload [stroke systemic vascular
resistance index (SSVRI)], the inotropy [inotropic state
index (ISI)], the left ventricular contractility [left stroke work
index (LSWI), ejection phase contractility index (EPCI)] and
thoracic fluid conductivity (TFC). The inotropic state index
(ISI) and left stroke work index (LSWI), were used to
estimate the intravascular volume according to the
Frank–Starling Law and indicated as quotient of the values
(LSWI/ISI) [20].
Analysed (n = 77)
• ABPM 
• Non-invasive hemodynamic 
measurement (HOTMAN
System) 
• OBP (Mobil-O-Graph 24-h PWA) 
• Blood test
Randomization
Follow-up visit
Monotherapy 4 weeks of treatment according 
to randomization (1:1:1:1 ratio)
Analysis 
Discontinued intervention (n = 8) : 
• Declined (n = 3) 
• Medical (gout, atrial 
fibrillation) (n = 2) 
• Change of monotherapy (n = 2) 
• Discontinued therapy (n = 1) 
Excluded due to technical problem (n = 3) 
ABPM 
Baseline sampling
Enrollment
Patients with established diagnosis of 
primary arterial hypertension (n = 88) 
• Exclusion of patients not meeting 
inclusion criteria
Control group with normotension (n = 20) 
• Exclusion of patients not meeting 
inclusion criteria
• Informed consent form 
• Non-invasive hemodynamic 
measurement (HOTMAN System) 
• OBP (Mobil-O-Graph 24-h PWA) 
• Blood test 
• Informed consent form 
• Non-invasive hemodynamic 
measurement (HOTMAN System) 
• OBP (Mobil-O-Graph 24-h PWA) 
• Blood test 
FIGURE 1 Overview about the study procedure. ABPM: ambulatory blood pressure measurement; OBP office blood pressure measurement, PWA: pulse wave analysis.
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The system also generated a graph showing the patient’s
hemodynamic status (i.e. their hemodynamic profile) in a
hemodynamic map marking the deviations (in þ/-%) of
volemia, inotropy, vasoactivity, and chronotropy from their
normal range (a function of age, sex, and clinical state) as
exemplary shown in Supplementary digital Figure 1, http://
links.lww.com/HJH/B545 [10].
Blood pressure measurements
The mean of the second and third BP measurement was
determined as OBP. ABPM was repeated after 4 weeks of
treatment. The awake and asleep time was taken from
patient’s protocol. According to the ABPM, patients were
categorized as having or having not reached BP targets
according to the 2013 ESH guidelines for management of
arterial hypertension [18]. Controlled blood pressure was
defined as mean 24-h, awake and asleep BP values within
normal ranges defined by the 2013 ESH guidelines, namely
less than 130/80 mmHg, less than 135/85 mmHg, and less
than 120/70mmHg.
Control group
A control group of 20 age-matched and gender-matched,
healthy and normotensive participants were recruited to
examine the hemodynamic characteristics at baseline in a
normotensive population. After having provided written
informed consent, normotension was documented with
ABPM. In this normotensive control group, OBP measure-
ments and hemodynamic measurements with the HOTMAN
device were taken at a baseline visit.
Allocation to concordant or discordant
treatment group
To investigate whether hemodynamic-guided choice of
antihypertensive therapy may improve BP control, three
hypertension experts retrospectively reviewed hemody-
namic measurements. Therefore, the experts followed
the following steps:
At first, the system-generated hemodynamic profiles
were subclassified in main hemodynamic pattern sub-
groups according to the percent-deviations of volemia,
inotropy, vasoactivity, and chronotropy: hypervolemia
without vasoconstriction pattern, hypervolemia with vaso-
constriction (mixed) pattern and vasoconstriction without
hypervolemia pattern group.
In a second step, baseline system-generated hemody-
namic maps of each patient were reviewed by all three
experts separately. They determined independently the
most appropriate treatment according to the individual
hemodynamic situation and the anticipated pharmacologi-
cal effects of the antihypertensive drugs (e.g. HCT for
patients with hypervolemia without vasoconstriction, ACEi
or ARB for mixed profiles with vasoconstriction and hyper-
volemia, or CCB for profiles with predominant vasocon-
striction). To reduce bias, they were blinded about patient
characteristics, assigned treatment and treatment effect after
4 weeks. After independent judgement, evaluation was
compared and the majority response was determined as
treatment of choice. This result was compared to the
allocated treatment and patients thus categorized as having
received concordant (ConTG) or discordant (DisTG) treat-
ment. As example, in a patient with hypervolemia without
vasoconstriction, the most appropriate treatment was
judged to be HCT. If this patient was randomized to
HCT, he was categorized in the concordant treatment group
(ConTG), but if he was randomized to a ACEi, ARB, or CCB,
he was then categorized in the discordant treatment group
(DisTG).
Statistical methodology
Findings were descriptively presented in graphs. Normal
distribution was assessed (Shapiro–Wilk W test), normally
distributed results were summarized in means and standard
deviation, not-normally distributed results were summa-
rized in medians and its interquartile ranges. Normally
distributed values were compared with independent sam-
ple t test analysis and the not-normally distributed were
analysed with the Mann–Whitney U test, using IBM SPSS
Statistics Version 22 (IBM, Armonk, New York, USA). The
Violin plots graphs were done using R, Version 3.6.0 (R
Foundation, Vienna, Austria). Dichotomous variables were
given as absolute numbers in percentage and compared
with the Fisher’s exact test. P value less than 0.05 was
defined as statistical significant.
RESULTS
Baseline characteristics
Baseline characteristics of the hypertensive and the control
group are displayed in Table 1. In the hypertensive group,
median (IQR) age, BMI, and gender proportion were 48.6
(36.1–59) years, 26.5 (23.8–29.0) kg/m2, and 74% men,
respectively, at baseline. The median age and gender
proportion in the hypertensive group differed not signifi-
cantly in the control group [50.2 (37.8–60.4) years, P¼ 0.816
and 70% men, P¼ 0.737, respectively]. The BMI was signif-
icantly higher in the hypertensive group than in the control
group [26.5 (23.8–29.0) vs. 22.2 (21.1–24.7) kg/m2, respec-
tively, P < 0.0005].
The median 24-h SBP/DBP by ABPM was 139.0 (135.0–
148.0)/89.0 (82.0–94.0) mmHg among the hypertensive
group compared with 121 (113.5–124.8)/76 (70.0–77.8)
mmHg (P< 0.0005/<0.0005) in the control group. The
LSWI/ISI and SSVRI were statistically significantly higher
among the hypertensive group compared with the control
group [LSWI/ISI 71.0 (63.4–79.3) vs. 62.2 (55.2–64.2),
P< 0.0005 and SSVRI 188.9 (145.9–249.2) vs. 147.5
(108.2–192.6), P¼ 0.004]. There was no statistically signif-
icant difference for the other hemodynamic values
between the two groups. Further blood pressure results
and the main hemodynamic values are summarized in
Table 1.
System-generated hemodynamic profiles at
baseline
At baseline, the system-generated hemodynamic profiles
were rated as normal in 10% of the control group and in 1%
of the hypertensive group. In the hypertensive group,
hypervolemia with vasoconstriction (mixed) was the pre-
dominant hemodynamic profile in 48% and hypervolemia
Glinz et al.
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without vasoconstriction in 45%, whereas in the control
group, 50% showed a profile of hypervolemia without
vasoconstriction, 15% hypervolemia with vasoconstriction
(mixed), and 15% vasoconstriction without hypervolemia
(Fig. 2).
As previously described in the methods, the HOTMAN
system provides deviations from normal range of the main
hemodynamic parameters: volemia, inotropy, vasoactivity,
and chronotropy. Supplementary digital Figure 2, http://
links.lww.com/HJH/B546 shows the distribution of these
deviations (in percentage) in the hypertensive group and in
the control group. It shows that the percentage-deviation of
hypervolemia from normal range is higher among the
hypertensive group than in the normal group. The percent-
age-deviation of vasoconstriction is also higher among the
hypertensive group compared with the control group.
Figure 2 and Supplementary digital Figure 2, http://link-
s.lww.com/HJH/B546 also show that the distribution of
these parameters among the control group are not mainly
in the ‘normal’ range and that normotension does not equal
to normovolemia.
Randomization to treatment
In the DisTG, 44.2% received either ACEi or ARB (RAASi
Group), 36.5% CCB and 19.2% HCT (52 patients in total). In
the ConTG, (25 patients in total), 64% received ACEi or ARB
(RAASi Group), 8% CCB, and 28% HCT.
Analysis of blood pressure measurements at
baseline
At baseline, the mean (SD) 24-h BP was 139.4 (7.5)/86.4
(7.3) mmHg in the DisTG and 146.3 (10.4)/91.0 (7.9)
mmHg in the ConTG (P¼ 0.001/0.015). The mean awake
BP was 145.0 (7.9)/90.6 (7.6) mmHg in the DisTG and
150.4 (9.9)/94.7 (8.3) mmHg in the ConTG (P¼ 0.011/
0.034). ABPM and OBP values at baseline and after 4 weeks
of treatment including BP response in the DisTG and the
 
45%
48%
3% 1%
3%
50%
15%
15%
10%
10%
Hypervolemia without
vasoconstricon
Vasoconstricon and
hypervolemia (mixed)
Vasoconstricon
without hypervolemia
Normal
Others
(a)                                                                             (b)
FIGURE 2 Hemodynamic profiles at baseline among treatment-naive hypertensive patients. (a) (N¼77) and control group (b) (N¼20).
TABLE 1. Characteristics at baseline among hypertensive and control group
Hypertensive group (N¼80) Control group (N¼20) P valueb
Sex, N male (%)/total 59 (73.8%)/80 14 (70.0%)/20 0.737
Age (years) 48.6 (36.1–59.0) 50.2 (37.8–60.4) 0.816
Height (m) 1.75 (1.69–1.81) 1.77 (1.69–1.82) 0.560
Weight (kg) 81.0 (71.0–89.0) 74.0 (64.5–77.0) 0.016
BMI (kg/m2) 26.5 (23.8–29.0) 22.2 (21.1–24.7) <0.0005
24-h HR 75.0 (69.0–82.0) 66.5 (65.0–74.5) 0.009
24-h SBP/DBP 139.0 (135.0–148.0)/89.0 (82.0–94.0) 121 (113.5–124.8)/76 (70.0–77.8) <0.0005/<0.0005
Awake SBP/DBP 145 (140.0–151.0)/92 (87.0–99.0) 124.5 (116.8–128.8)/78.5 (73.3–82.0) <0.0005/<0.0005
Asleep SBP/DBP 126.0 (119.0–136.0)/78.0 (69.0–83.0) 108.0 (99.3–112.0)/63.5 (58.3–67.8) <0.0005/<0.0005
sOBP/dOBP 139.5 (131.5–147.5)/90.0 (83.5–97.5) 126.0 (111.8–131.3)/78.0 (74.0–80.0) <0.0005/<0.0005
CI (l/min per m2) 3.0 (2.2–3.5)a 3.0 (2.5–3.7) 0.414
SI (ml/m2) 43.0 (32.0–55.0)a 48.0 (38.0–70.5) 0.152
ISI (s1) 0.9 (0.69–1.1)a 1.0 (0.79–1.35) 0.075
LSWI (g.m/m2) 61.1 (47.3–81.0)a 57.3 (41.5–84.7) 0.855
LSWI/ISI 71.0 (63.4–79.3)a 62.2 (55.2–64.2) <0.0005
SSVRI (FV) 188.9 (145.9–249.2)a 147.5 (108.2–192.6) 0.004
TFC (V1) 0.03 (0.03–0.03)a 0.03 (0.03–0.03) 0.469
EPCI (s1) 0.04 (0.03–0.05)a 0.04 (0.04–0.06) 0.084
Variables are expressed as median (IQR). CI, cardiac index; dOBP, diastolic office blood pressure; EPCI, ejection phase contractility index; HR, heart rate; ISI, inotropic state index; LSWI,
left stroke work index; SI, stroke index; sOBP, systolic office blood pressure; SSVRI, stroke systemic vascular resistance index; TFC, thoracic fluid conductivity.
aN¼77 hypertensive group.
bMann –Whitney U test.
Hemodynamic profiles in hypertension
Journal of Hypertension www.jhypertension.com 5
CE: Tripti; JH-D-20-01167; Total nos of Pages: 8;
JH-D-20-01167
ConTG are summarized in Supplementary digital Table 2,
http://links.lww.com/HJH/B548.
Analysis of blood pressure measurements after
4 weeks of treatment
After 4 weeks of treatment, the mean (SD) 24-h BP was
129.9 (11.0)/81.5 (8.0) mmHg in the DisTG vs. 133.9
(12.3)/84.0 (9.1) mmHg in the ConTG (P¼ 0.158/0.222).
The mean awake BP was 134.5 (11.5)/85.5 (8.3) mmHg
in the DisTG and 137.6 (12.8)/87.2 (9) mmHg in the
ConTG (P¼ 0.294/0.428). The 24-h, awake and asleep BP
measurements after 4 weeks of treatment among the
ConTG and DisTG are shown in Fig. 3. ABPM and OBP
values at baseline and after 4 weeks of treatment including
BP response in the DisTG and the ConTG are summarized
in Supplementary digital Table 2, http://links.lww.com/
HJH/B548.
The mean 24-h BP reductions were 9.7 (10.1)/5.0
(6.2) mmHg in the DisTG and 12.4 (14.8)/6.9 (6.9)
mmHg in the ConTG (P¼ 0.353/0.223), meaning a SBP/
DBP reduction of 7%/5.8% in the DisTG and 8.5%/7.6% in
the ConTG. The mean BP reductions after 4 weeks of
treatment are shown in Fig. 4.
Blood pressure control rate after 4 weeks of
treatment
After 4weeksof treatment, theBPcontrol ratewas53.7% (43/
80) among all, 55.7% (29/52) in the DisTGand 48% (12/25) in
the ConTG (P¼ 0.6275 DisTG vs. ConTG, Fisher’s Test).
DISCUSSION
Our study showed that in patients with treatment-naive
hypertension, the predominant hemodynamic profiles at
baseline were hypervolemia without vasoconstriction and
hypervolemia with vasoconstriction (mixed). Hypervole-
mia was clearly the predominant component in the hemo-
dynamic profiles (93%) among hypertensive but otherwise
asymptomatic patients (without clinical signs of volume
overload). The predominance of these mixed profiles
(hypervolemia and vasoconstriction) and of hypervolemia
as single modulator have also been shown in a previous
study among uncontrolled hypertensive patients also using
the HOTMAN System [8].
Interestingly, only 10% of normotensive control patients
in our analysis showed a normal system-generated hemo-
dynamic profile with all modulators within normal range.
The predominant hemodynamic profile among the control
group was a mixed pattern of hypervolemia with vasocon-
striction. Regarding single modulators, hypervolemia was
again the most prevalent – but compared with the hyper-
tensive group the degree of the deviation from normal
range was lower.
Reasons for these observations may be: firstly, calculated
values of the HOTMAN System can be biased. These
calculations are based on a physiologic model with ideal
stroke index (SI) and mean arterial pressure (MAP) range
and the hemodynamic profiling is related to the accuracy of
the measurements namely the thoracic bioimpedance and
the noninvasive blood pressure. Their accuracy can be
FIGURE 3 Ambulatory blood pressure monitoring at baseline and after 4 weeks of treatment, among discordant treatment group and concordant treatment group. (a) 24-
h SBP/DBP; (b) awake SBP/DB; (c) asleep SBP/DBP. Blue box, SBP at baseline; green, SBP after 4 weeks; beige, DBP at baseline; violet, DBP after 4 weeks. X-axis, DisTG and
ConTG; Y axis, BP in mmHg.
FIGURE 4 Mean blood pressure reduction in mmHg after 4 weeks of treatment (a) 24-h SBP/DBP; (b) awake SBP/DBP; (c) asleep SBP/DBP. Blue box: mean reduction of
SBP; green, mean reduction of DBP. X axis, DisTG and ConTG; Y axis, mmHg.
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altered depending on the clinical conditions of the mea-
surement [10]. Therefore, the interpretation of the ‘normal’
or ‘not normal’ hemodynamic profile should be used cau-
tiously and only under consideration of the clinical state of
the patient. Secondly, we assume that hemodynamics are a
continuum with the possibility of dysregulation of one
hemodynamic modulator and counter-regulation by
another. Therefore, a normotensive status does not neces-
sarily correspond to a hemodynamic profile within the
normal range. BP can be seen as continuum, too, with
arbitrary defined ranges and cut-off values. Therefore, not
hypertensive individuals can be subdivided into optimal,
normal, or prehypertensive with beginning hemodynamic
alterations [4]. As consequence, in our analysis, deviation
from a normal state were more pronounced in the hyper-
tensive group than in the control group.
Additionally, we investigated whether an individualized
approach of hemodynamic-guided therapy could have the
potential to improve BP control within 4 weeks. Theoreti-
cally, a tailored therapy based on the hemodynamic alter-
ations, and thus the individual pathophysiology should
provide a more effective BP reduction. Though the 24-h
BP reductionwasmorepronounced in theConTGcompared
with the DisTG with a SBP/DBP reduction of12.4 (14.8)/
6.9 (6.9) mmHg vs.9.7 (10.1)/5.0 (6.2) mmHg, the
differences were not statistically significant. Additionally, the
control rate after 4weekswasnothigher in theConTGgroup.
Consequently, we found no advantage of a personalized
monotherapy over discordant monotherapy.
This may have several reasons: the average SBP at base-
line was, by chance, significantly (7mmHg) lower in the
DisTG than in the ConTG. This may lead to a more pro-
nounced blood pressure reduction in the ConTG group
becauseof thehigher baselineBPvalues at therapy initiation,
and a lower control rate in the ConTG group, as the DisTG
group started closer to the BP targets. This effect is purely by
chance, as the patients were randomly assigned to the four
treatment groups and only post hoc labelled as ConTG or
DisTG based on their hemodynamic profile. Keeping these
points in mind, the difference in BP reduction may be even
lower in a large randomized controlled trial (RCT) comparing
ConTG to standard therapy with a more balanced baseline
BP between both groups. When we consider that in our
post hoc analysis, we decided dichotomously between a
concordant treatment vs. a discordant treatment, and in a
prospective intention-to-treat RCT, we would rather use a
randomization to hemodynamically guided (concordant) vs.
usual treatment, the treatment effect might even diminish, as
in the usual treatment group, some patients will be treated
concordantly by chance aswell. At least, treatment effects are
usually overestimated in studies with lower patient numbers
than in larger randomized trials.
Our neutral results are consistent with the findings of the
BEAUTY Study, which showed that noninvasive hemody-
namic assessment combined with a drug selection algo-
rithm did not result in a better reduction of daytime SBP in
ambulatory BP monitoring among uncontrolled hyperten-
sive patients [16]. The subanalysis of home BP measure-
ments in the BEAUTY study; however, showed that the
drug selection based on hemodynamic monitoring signifi-
cantly improved home BP after 6 months compared with
the control group (P¼ 0.002) [17]. Similarly, a randomized
prospective controlled trial in 2016 using impedance car-
diography (ICG)-guided antihypertensive therapy showed
a greater BP reduction in the ICG-guided group among the
patients with higher BP but did not significantly reduce BP
among patients with slightly elevated BP [21].
Hemodynamics in arterial hypertension are complex,
‘intrigate’ each other, and cannot be resumed as four
independent parameters. Lowering BP, for example, by
vasodilation can lead to an activation of the RAAS system,
and volume reduction can lead to a compensatory vaso-
constriction. Other studies have shown that HCT raises
angiotensin II, probably because of a decreased renal blood
flow, which leads to an activation of the RAAS system [22].
Therefore, the lack of predictability of response to treat-
ment based on noninvasive hemodynamics and the results
of predominantly mixed hemodynamic profiles supports
the recommendation of the current European Society of
Cardiology (ESC)/ESH guidelines to initiate treatment as a
combination of at least two active agents, which would be
even more difficult to predict by noninvasive hemodynam-
ics. Additionally, we observe only a control rate of 56% of
patients after 4 weeks of monotherapy.
There were several limitations in this study. First, the post
hoc analysis was made on a study focusing on changes in
RAAS peptide profiles and hemodynamics after random-
ized treatment initiation. There was a disbalance in the
number of patients in the ConTG and DisTG as well as
differences in the baseline BP values. Retrospective alloca-
tion to the ConTG or DisTG was done by hypertension
experts, however, we cannot exclude a bias in the process
of the allocation. This allocation was done based on the
results of the hemodynamic measurements with blinding
for treatment, the other’s results, as well as treatment effects.
To date, the noninvasive measures with the HOTMAN
system are not a clinical standard, even if the device has
been used in several trials.
The present analysis has several strengths: all hemody-
namic and BP measures were performed under standard-
ized conditions at the same center and a complete follow-
up was achieved at 4 weeks. A 24-h BP measurement was
used as both an inclusion criteria and as follow-up parame-
ter. The parallel evaluation of the hemodynamic profiles by
three experts might be not generalizable for a broader
group but was on purpose clinically oriented and aimed
to simulate the every-day decision-making when personal-
ized hemodynamic profiles are available.
In conclusion, findings of the present analysis describe
mainly mixed hemodynamic profiles with hypervolemia
and vasoconstriction in patients with newly diagnosed
hypertension. They do not support the hypothesis that
personalized treatment initiation based on hemodynamic
profiles improves BP control in comparison to randomized
treatment assignment in newly diagnosed hypertensive
outpatients.
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